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Abstract
Rationale: Though matrix metalloproteinases (MMPs) are critical in the pathogenesis of COPD, their utility as a disease
biomarker remains uncertain. This study aimed to determine whether bronchoalveolar lavage (BALF) or plasma MMP
measurements correlated with disease severity or functional decline in emphysema.
Methods: Enzyme-linked immunosorbent assay and luminex assays measured MMP-1, -9, -12 and tissue inhibitor of matrix
metalloproteinase-1 in the BALF and plasma of non-smokers, smokers with normal lung function and moderate-to-severe
emphysema subjects. In the cohort of 101 emphysema subjects correlative analyses were done to determine if MMP or
TIMP-1 levels were associated with key disease parameters or change in lung function over an 18-month time period.
Main Results: Compared to non-smoking controls, MMP and TIMP-1 BALF levels were significantly elevated in the
emphysema cohort. Though MMP-1 was elevated in both the normal smoker and emphysema groups, collagenase activity
was only increased in the emphysema subjects. In contrast to BALF, plasma MMP-9 and TIMP-1 levels were actually
decreased in the emphysema cohort compared to the control groups. Both in the BALF and plasma, MMP and TIMP-1
measurements in the emphysema subjects did not correlate with important disease parameters and were not predictive of
subsequent functional decline.
Conclusions: MMPs are altered in the BALF and plasma of emphysema; however, the changes in MMPs correlate poorly with
parameters of disease intensity or progression. Though MMPs are pivotal in the pathogenesis of COPD, these findings
suggest that measuring MMPs will have limited utility as a prognostic marker in this disease.
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Introduction
In COPD, MMPs contribute to airway obstruction by triggering
dysfunctional matrix remodelling [1] and inducing inflammation
[2]. Tissue destruction in this disease results from an imbalance in
protease/antiprotease activity such as MMPs and their inhibitors,
tissue inhibitors of metalloproteinases (TIMPs) [3–5]. The
collagenase MMP-1, the gelatinase MMP-9 and the metalloelas-
tase MMP-12 are of particular interest in emphysema pathogen-
esis. MMP-1 is up regulated in alveolar walls and macrophages in
human emphysema [6,7] and the transgenic expression of human
MMP-1 in mice, which lack the gene for MMP-1, generates adult-
onset emphysema, associated with a loss of lung compliance [8].
Similarly, MMP-9 levels are elevated in the lung [5] and alveolar
macrophages of COPD patients [4,9]. Indeed, circulating
monocytes of advanced emphysema subjects have the highest
levels of MMP-9 production [10] and the expression of this
protease in alveolar macrophages causes progressive adult-onset
emphysema in mice [11]. The metalloelastase, MMP-12, was
shown to be required for cigarette smoke-induced emphysema in
mice [12]. Furthermore, sputum MMP-12 concentrations corre-
late with the extent of emphysema as determined by CT [13] and
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polymorphisms in the MMP-12 promoter have been associated
with changes in lung function [14,15]. Given their importance,
this study aimed to determine whether MMP-1, -9, -12 and
TIMP-1 (tissue inhibitor of matrix metalloproteinase-1) levels
measured in the bronchoalveolar lavage fluid (BALF) and plasma
of advanced emphysema subjects were predictive of the severity
and future course of the disease.
Methods
Selection Criteria for Study Participants
Emphysema BALF samples were obtained from baseline
measurements of Feasibility of Retinoids for the Treatment of
Emphysema (FORTE) trial participants [16]. Briefly, subjects
were over 45 years of age with an FEV1 25 to 80% of predicted, a
reduced diffusing capacity of the lung for carbon monoxide (DLco)
and emphysema documented on chest CT scan. Of note, subjects
were clinically stable and were excluded if there was history of
recent history of exacerbation of systemic corticosteroid use. All
included emphysema participants had abstained from tobacco use
for at least 6 months, confirmed by a serum cotinine level of less
than 20 ng/ml. Analysis included 101 FORTE trial participants
with moderate to severe emphysema, 17 current smokers with
normal pulmonary function as well as 72 volunteers with no
significant respiratory disease and no smoking history. Written
consent was obtained from all study participants and the trial was
approved by the institutional review boards of Columbia
University Medical Center, the University of Pittsburgh, the
University of California at Los Angeles Medical Center, the
University of California at San Diego Medical Center, Boston
University Medical Center and Long Island Jewish Medical
Center.
Outcomes Measurements
Pulmonary function tests were conducted by qualified personnel
in accordance with American Thoracic Society standards [17],
with predicted values according to Hankinson et al [18] and
Crapo et al [19]. The overall respiratory status was assessed with
the St. George Respiratory Questionnaire (SGRQ) [20]. Radiol-
ogy technologists were trained in a standard imaging protocol
across the various study centers as previously reported [16]. A
water phantom (GE; Milwaukee, WI) was scanned at each center,
and the reconstruction kernels were selected to provide equivalent
images across institutions [21]. Ten-millimeter collimation was
used (no overlap), and images were transmitted in digital format to
the Radiology Core. Image analysis was performed to determine
lung volume and the percentage of emphysema by density mask
(percentage of total lung voxels,2 910 Hounsfield units [HU])
[22]. Density mask scores were not adjusted for CT-measured lung
volume due to possible independent effects of treatment on these
parameters.
Bronchoscopy Procedure
Fiberoptic bronchoscopy was performed on an outpatient basis
in the endoscopy units of the participating study centers as per
standard protocol. Bronchoscopy details for this study have been
previously described [16,23].
Measurement of Protease Activity
Collagenase and elastase activity was measured from the BALF
of non-smoking controls, smokers and emphysema subjects.
Collagenase units were calculated as the number of mmoles of
leucine liberated per mg of enzyme, by a colorimetric ninhydrin
method [24,25]. Elastase activity was measured by the hydrolysis
of N-succinyl-L-Ala-L-Ala-L-Ala-p-nitroanilide (Suc Ala3NA) per
minute at 25uC and pH 8.0 under the specified conditions [26,27].
Processing of BALF and Plasma Samples
BALF and plasma was processed as previously reported [16].
Once obtained the BALF fluid was filtered with a sterile Falcon
100-micron nylon mesh to remove mucus and debris. The fluid
was then centrifuged at 2006g for 15 minutes at 4uC. The BALF
supernatant was aliquoted and immediately stored on-site in a
280uC freezer. Aliquots were shipped frozen from the testing sites
to Columbia University for determination of matrix metallopro-
teinase levels. Approximately 30 ml of blood was obtained via
venipuncture into three 10 ml heparinized tubes. These tubes
were then centrifuged at 2006g for 8 minutes at 4uC. The plasma
was transferred into labeled 1.5 ml tubes and stored at 270uC to
280uC on-site until they were ready to be shipped as described
above.
Determination of Matrix Metalloproteinase-1, -9, -12 and
Tissue Inhibitor of Metalloproteinase-1 Levels
ELISAs for MMP-1, -9 and TIMP-1 (Amersham Biosciences,
Piscataway, NJ, USA) were conducted on BALF and plasma of the
entire emphysema cohort (101 subjects). MMP-12 levels were
measured in the BALF (N= 66 emphysema subjects) and plasma
(N= 49 emphysema subjects) using a Luminex assay (Invitrogen,
Table 1. Patient Demographics.
Non-smokers Smokers Emphysema
Number 72 17 101
Age (years) 24.263.7 26.164.8 65.567.5
Gender (Male/Female) 60%/40% 76%/24% 57%/43%
Race (Caucasian/African-American) 88%/12% 76%/24% 100%/0%
Mean Smoking History (years) 060 7.861.6 58.4629.9
Data are presented as mean 6 standard deviation.
doi:10.1371/journal.pone.0056352.t001
Table 2. Emphysema characteristics.
Current smokers 0
Average cigarettes per day prior to smoking cessation 31.1615
Pack years 58.4629.9
FEV1 46612.7
FVC 82.5614.3
FEV1/FVC 42.269.5
Bronchodilator responsiveness 13.1610.2
Total lung capacity 116.6615.1
Residual volume 166.6641.2
DLCO 39.2611.8
CT % Emphysema (HU,2910) 37.9612.8
All data are presented as mean 6 standard deviation. Data for forced expiratory
volume in one second (FEV1), forced vital capacity (FVC) total lung capacity,
residual volume and diffusion capacity for carbon monoxide (DLCO) are all
presented as percent predicted. FEV1/FVC ratio is presented as %.
Bronchodilator responsiveness is presented as % change in FEV1.
doi:10.1371/journal.pone.0056352.t002
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Carlsbad, CA, USA). Since the original plasma determinations
had been only conducted on emphysema subjects, repeat plasma
analyses for MMP-1, -9, -12 and TIMP-1 were conducted using
Luminex multiplex (Invitrogen, Carlsbad, CA, USA) to compare
MMP plasma levels between study emphysema subjects and
controls (5 age-matched smokers, 15 age-matched non-smokers
and 49 emphysema subjects).
Statistical Analysis
All data analysis was performed using GraphPad Prism software
(La Jolla, CA, USA). Significant differences in levels between the
cohorts were assessed by the Kruskal-Wallis one-way analysis of
variance by ranks followed by the Dunn’s multiple comparison
test. Wilcox signed rank tests were conducted to examine
difference between individual cohorts. Mann-Whitney tests were
utilized to determine significant differences between quartiles of
MMP expression. These non-parametric analyses were chosen due
to the skewed distribution of the results. A p-value of ,0.05
considered statistically significant. Coefficient of determination
and linear regression analyses were conducted to examine the
association between MMPs levels as determined by ELISA or
Luminex (MMP-12) and key disease parameters.
Results
Baseline Patient Characteristics
For the lavage studies, subjects with emphysema were older
than the non-smoking controls and smokers without emphysema
(Table 1). Plasma samples were well matched by age across the
three cohorts. The 101 emphysema subjects exhibited at least
moderately severe airway obstruction in pulmonary function
testing and had visual evidence of emphysema occupying$10% of
the lung on CT (Table 2).
MMP Levels in Emphysema, Smokers and Normal
Controls
Significant increases in BALF MMP-1 protein levels
(0.864.5 ng/ml in control, 3.063.0 ng/ml in smokers,
2.763.0 ng/ml in emphysema; p,0.0001 by Kruskal-Wallis test,
all data are presented as mean 6 standard error) (Figure 1A) and
MMP-9 protein levels (2.169.2 ng/ml in control, 7.5615.4 ng/
ml in smokers, 24.9644.7 in emphysema; p,0.0001 by Kruskal-
Wallis test) (Figure 1B) were detected amongst the three cohorts.
Analyses between paired groups showed that MMP-1 and -9 levels
in smokers and emphysema subjects were significantly increased
compared to non-smoking controls. Though BALF MMP-12
levels were altered amongst the study cohorts (1.760.1 ng/ml in
control, 2.060.3 ng/ml in smokers, 11.864.7 ng/ml in emphy-
sema; p,0.004 by Kruskal-Wallis test) (Figure 1C), only controls
and emphysema subjects showed a significant intergroup differ-
ence. BALF TIMP-1 levels were also altered amongst the three
study cohorts (TIMP-1 4.267.2 ng/ml in control, 11.5611.8 ng/
ml in smokers, 127.86189.7 in emphysema; p,0.0001 by
Kruskal-Wallis test) (Figure 1D). BALF TIMP-1 levels were higher
in smokers and emphysema subjects compared to controls and
those with emphysema had even higher levels than active smokers
(Figure 1D). Though MMP-1 levels were comparable in smokers
and emphysema subjects, only those with emphysema had
significantly increased collagenase activity (Figure 1E). Moreover,
this increase in activity occurred despite the fact that TIMP-1
levels were notably higher in the emphysema cohort compared to
the smoking group. Elastase activity, on the other hand, was
increased in both the smokers and the emphysema subjects
(Figure 1F). The MMP-1/TIMP-1 (Figure 1G) and MMP-9/
TIMP-1 (Figure 1H) ratios were comparable amongst the three
cohorts. In comparison to BALF, MMP-1 plasma levels were
higher in active smokers than they were in the control or
emphysema cohort (Figure 2, top panel) (7.35 ng/ml in control,
14.27 ng/ml in smokers and 8.20 ng/ml in emphysema;
p,0.0001 by Kruskal Wallis test) and MMP-9 (19.76 ng/ml in
control, 18.6 ng/ml in smokers and 7.93 ng/ml in emphysema;
p,0.0001 by Kruskal Wallis test) and TIMP-1 levels (94.49 ng/ml
in control, 92.93 ng/ml in smokers and 26.36 ng/ml in emphy-
sema; p,0.0001 by Kruskal Wallis) were significantly lower in the
emphysema cohort compared to both the control and smoker
groups (Figure 2, center and bottom panels).
MMP Levels and Disease Parameters in Emphysema
To assess correlation with disease severity, BALF and plasma
MMP-1, -9, -12 and TIMP-1 levels were broken down into
quartiles of protein expression in the emphysema subjects
(Table 3). Analyses were then conducted to determine if increasing
quartiles of protein expression were associated with age, pack
years, FEV1% predicted, FEV1/FVC % predicted, TLC %
predicted, CT score or St. George questionnaire total score
(Tables 4 and 5). Age was associated with higher quartiles of
MMP-9, -12 and TIMP-1 BALF protein levels and the highest
quartile of MMP-9 plasma protein expression was associated with
increased TLC % predicted. In contrast to a prior study [13],
higher MMP-12 levels were associated with lower emphysema
scores on CT. However, after adjustment for multiple compari-
sons, these differences were no longer statistically significant.
Linear regression analyses were conducted comparing baseline
BALF MMP values with D DLCO and FEV1/FVC % predicted
at 9 months (Figure 3). No significant associations were found.
Similarly, we found no correlation between BALF elastase and
collagenase activity and COPD disease parameters (Table 6).
Baseline BALF and plasma MMP-1, -9 and -12 levels correlated
poorly with follow up measurements performed 3 to 6 months
later (Figure 4) despite the fact that the emphysema subjects were
in a stable disease state [23]. TIMP-1 levels, on the other hand,
demonstrated greater consistency over time with TIMP-1 follow
up plasma levels showing a very strong correlation with baseline
values.
Predictive Value of MMP Levels in COPD
To address whether MMP levels taken from a COPD subject
were predictive of the future course of the disease, baseline MMP
or TIMP values were correlated with the change in FEV1 over
time. BALF (Figure 5) and plasma (Figure 6) baseline MMP and
Figure 1. BALF MMP and TIMP-1 protein levels and protease activity in controls, smokers and emphysema subjects. BALF was
performed on 72 normal control subjects, 16 smokers, and 101 subjects with moderate to severe emphysema who had refrained from smoking for at
least six months. (A) MMP-1, (B) MMP-9, (C) MMP-12 and (D) TIMP-1 protein levels were recorded. p,0.0001 by Kruskal-Wallis one-way analysis of
variance by ranks followed by a Dunn’s multiple comparison test. p values shown, comparing both treatments connected by a line. (E) Collagenase
and (F) elastase activity were measured in the BALF of 26 normal controls, 9 smokers without emphysema and 60 emphysema subjects. Differences
between cohorts was assessed by ANOVA; p,0.05. (G) MMP-1/TIMP-1 BALF ratios and (H) MMP-9/TIMP-1 BALF ratios were determined in the BALF of
82 normal controls, 18 smokers without emphysema and 98 emphysema subjects. Differences between cohorts was assessed by ANOVA; p,0.05.
doi:10.1371/journal.pone.0056352.g001
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TIMP levels correlated poorly with the change in FEV1 at 6, 9
and 18 months follow up. Plasma MMP-12 was not analyzed since
MMP-12 was not detectable in the plasma.
Correlation between MMP BALF and Plasma Protein
Levels in Emphysema
Linear regression analyses compared simultaneous BALF and
plasma MMP-1, MMP-9, and TIMP-1 measurements in COPD
subjects (Figure 7A). BALF and plasma levels showed a poor
correlation with each other. Linear regression analyses yielded an
R2 coefficient of determination less than 0.01 for each association.
Of note, these analyses were not conducted for MMP-12 since
plasma levels of MMP-12 were undetectable.
MMP/TIMP-1 Ratios in the BALF Samples
MMP/TIMP-1 ratios for MMP-1, -9 and -12 exhibited no
significant difference between groups. Though the overall ratios of
MMPs/TIMP-1 were not significantly altered, it is important to
note that the correlation between BALF MMP and TIMP-1 levels
was weak (Figure 7B). In fact, in the emphysema cohort, those with
high MMP levels frequently had very low levels of TIMP-1
indicating that a proteolytic imbalance is likely present within the
lung of the emphysema subjects.
Discussion
The discovery of new markers that better correlate with disease
severity and progression would provide important prognostic
information for patients and physicians and greatly decrease the
time and expense needed to demonstrate clinical benefit of a
therapeutic agent [28]. Given the role of MMPs in the
pathogenesis of this disease, we investigated whether MMP levels
in the BALF or plasma could serve as a barometer of disease
activity. This study demonstrates that MMP levels are increased in
the BALF of patients with severe COPD; however, MMP levels by
themselves did not correlate with disease severity and were not
predictive of disease progression. Moreover, we found that
baseline BALF and plasma levels correlated poorly with follow
up measurements taken from the same individuals at a 3 or 6-
month follow up period. Moreover, baseline MMP measurements
did not correlate with changes in FEV1% predicted over an 18-
month time period of follow up. Together, these results indicate
that MMP levels in emphysema subjects are highly variable and
have limited utility as a biomarker in this disease.
Though MMP levels were a poor prognostic predictor in this
study, the increased MMP levels may reflect ongoing subtle disease
activity not detectable with the standard available clinical
measures over such a short period of time. Indeed, MMP levels
may need to be tracked in a very large cohort for years to
determine their effects on disease outcomes. Despite the high
TIMP-1 levels, elastase and collagenase activity were significantly
increased within the BALF of the emphysema cohort. What is
interesting to note is that collagenase activity was only increased in
the emphysema cohort. This was despite the fact that TIMP-1
levels were much higher in the emphysema cohort than the active
smokers. This may mean that the dysfunctional matrix remodeling
that leads to emphysema is not yet occurring in the smokers
despite their increased MMP levels. It is well known that MMPs
are increased in smokers even though not all these individuals will
go on to develop COPD [29]. These findings suggest that the
development of increased collagenolytic activity may represent a
key transition to the disease state in chronic smokers. However,
our results cannot address whether collagenase is a marker of
smoke exposure intensity or disease susceptibility. This question
will need to be explored in future longitudinal studies.
Unlike TIMP-1, MMP protein levels varied greatly in COPD
subjects over time. This intra individual variability in MMP levels
is unlikely to be due to technical factors. Bronchoscopy and plasma
Figure 2. MMP and TIMP-1 levels in the plasma of normal
smokers and emphysema subjects. Luminex multiplex assays for
MMP-1 (top panel), MMP-9 (center panel) and TIMP-1 (bottom panel)
were done on age-matched plasma samples from non-smoking
controls, normal smokers and subjects with moderate to severe
emphysema. MMP-12 was measured but levels were below the limit
of detection.
doi:10.1371/journal.pone.0056352.g002
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collection protocols were standardized across multiple centers and
all samples were handled in a uniform manner. While variable
return could affect lavage measurements, plasma MMP values,
which are less subject to variations in collection, were also not
stable in COPD subjects. Typically, baseline and follow up MMP
measurements were batched together on the same plate and
internal standards were used to ensure the reproducibility of our
results. In fact, the ELISA analyses in these studies demonstrated a
coefficient of variation of less than 20%. Importantly, emphysema
subjects were in a steady state clinically and had no systemic
steroid use and no history of recent exacerbation upon entry in the
trial [23]. This shows that single point determinations may not
reflect what is occurring in the lung over a prolonged period of
time. Future biomarker studies will need to perform sequential
testing in individual COPD subjects to address this important issue
of temporal variability.
The decrease in plasma MMP-9 and TIMP-1 levels that were
measured in the emphysema cohort contrasted with a recent study
that showed that serum levels of these proteins were elevated in
COPD [30]. It is important to note, however, that serum levels
Figure 3. Correlation between MMPs and DLCO or FEV1/FVC % predicted. Linear regression analyses correlated baseline BALF MMP-1, -9, -
12 and TIMP-1 lavage levels with change in DLCO or the FEV1/FVC % predicted ratio at 9-month follow up. R
2 = coefficient of correlation.
doi:10.1371/journal.pone.0056352.g003
Figure 4. Correlation between baseline and follow up BALF and plasma MMP/TIMP levels. Baseline BALF and plasma protein levels for
MMP-1, -9 and TIMP-1 were correlated with follow up MMP/TIMP levels that were collected and measured 3 or 6 months following the baseline tests.
The coefficient of determination (R2) was calculated for each value at each time point.
doi:10.1371/journal.pone.0056352.g004
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can be influenced by the release of MMPs following the
degranulation of leukocytes and platelets during the ex vivo
clotting process [31]. It is conceivable that circulating monocytes
that produced these proteins may have been preferentially drawn
to the lung thereby increasing lung while decreasing plasma levels.
Though this was one of the largest BALF and plasma analyses
conducted in COPD, it is conceivable that our study size was not
sufficient to detect the link between MMP levels and disease
severity and progression. A limitation of the BALF studies was the
large age discrepancy between the control subjects, smokers
without emphysema and study group. Though we cannot rule out
Table 3. Quartiles of MMP protein expression.
Lavage MMP-1 Lavage MMP-9 Lavage MMP-12 Lavage TIMP-1 Plasma MMP-1 Plasma MMP-9 Plasma TIMP-1
Minimum 0 0 0 0 0 0 39
25th % 1 1 2 12 2 6 238
Median 2 6 2 45 5 13 303
75th % 4 28 6 214 10 29 495
Maximum 12 220 267 865 200 200 1098
Mean 3 27 12 135 9 28 349
Minimum to 25% represented quartile 1 (Q1), 26% to Median represented quartile 2 (Q2), Median to 75% represented quartile 3 (Q3) and 75% to Maximum represented
quartile 4 (Q4).
doi:10.1371/journal.pone.0056352.t003
Table 4. Association between quartile of BALF protein expression and clinical parameters.
Parameter Quartile MMP-1 (Std. dev.) MMP-9 (Std. dev.) MMP-12 (Std. dev.) TIMP-1 (Std. dev.)
Age 1Q 67 (8) 62 (7) 61 (7) 63 (6)
2Q 66 (7) 65 (8) 65 (8) 65 (8)
3Q 67 (8) 68 (7) 67 (3) 68 (8)
4Q 63 (7) 68 (8) 71 (5) 68 (8)
Pack years 1Q 55 (22) 52 (26) 56 (24) 58 (29)
2Q 57 (24) 55 (24) 56 (23) 59 (25)
3Q 61 (37) 55 (21) 38 (6) 57 (37)
4Q 53 (29) 64 (39) 57 (25) 53 (21)
FEV1 1Q 48 (12) 44 (11) 49 (13) 44 (13)
2Q 47 (14) 48 (16) 46 (10) 47 (13)
3Q 46 (13) 46 (13) 48 (15) 47 (12)
4Q 45 (13) 49 (12) 52 (15) 48 (15)
FEV1/FVC 1Q 44 (10) 41 (8) 44 (10) 39 (9)
2Q 41 (10) 43 (13) 42 (9) 44 (9)
3Q 43 (9) 41 (9) 51 (7) 42 (10)
4Q 41 (11) 45 (10) 45 (10) 43 (11)
TLC 1Q 112 (17) 115 (10) 117 (18) 117 (12)
2Q 120 (14) 119 (18) 117 (15) 119 (17)
3Q 116 (12) 113 (14) 109 (15) 115 (13)
4Q 117 (17) 119 (16) 115 (14) 114 (18)
CT Score 1Q 36 (11) 40 (10) 41 (11) 41 (13)
2Q 39 (12) 40 (16) 37 (11) 36 (12)
3Q 35 (14) 37 (12) 21 (4) 35 (15)
4Q 39 (15) 34 (12) 28 (14) 39 (11)
St. George 1Q 35 (18) 34 (14) 33 (13) 35 (10)
Total 2Q 40 (11) 38 (14) 41 (17) 39 (13)
3Q 37 (13) 37 (13) 44 (11) 38 (16)
4Q 37 (12) 41 (14) 39 (18) 37 (15)
The mean values of age, pack years, FEV1% predicted, FEV1/FVC % predicted, TLC % predicted, CT score and St. George questionnaire total score were calculated for
each quartile of MMP-1, -9, -12 and TIMP-1 BALF protein expression. Bold indicates p,0.05 compared to quartile 1. Parentheses () indicate standard deviation.
doi:10.1371/journal.pone.0056352.t004
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age as a confounding factor, MMP levels in control subjects were very low for MMP-1, -9 and -12 as has been reported in other
studies of normal, non-smoking controls subjects [32,33]. Thus, it
is unlikely that these dramatic increases are due to age alone.
Though measuring MMPs may not be useful for the majority of
COPD patients, it may have a role for those with genetic
polymorphisms that cause persistent increases in MMP expression
[15,34]. Future research will need to address whether those
COPD subjects who do have stably high MMP levels undergo
more progression of their disease. Indeed, polymorphisms in
MMP-1, -9 and -12 have been reported to be associated with
COPD-related phenotypes[14,35–37].
In summary, these findings show that increases in BALF MMP
levels are not associated with disease severity or progression.
Moreover, these results demonstrate that MMP levels vary
considerably over time even in stable COPD subjects. Important-
ly, this study showed that BALF collagenase activity was increased
in emphysema and not in active ‘‘healthy’’ smokers. Further
studies will need to examine whether the presence of increased
collagenolytic activity within the lung heralds the development of
disease in active smokers.
Table 5. Association between quartile of plasma protein expression and clinical parameters.
Parameter Quartile MMP-1 (Std. dev.) MMP-9 (Std. dev.) TIMP-1 (Std. dev.)
Age 1Q 64 (8) 65 (7) 65 (8)
2Q 67 (7) 68 (7) 66 (9)
3Q 66 (8) 64 (7) 66 (6)
4Q 66 (8) 66 (10) 66 (8)
Pack years 1Q 64 (27) 63 (29) 50 (22)
2Q 50 (23) 52 (18) 47 (23)
3Q 51 (22) 56 (24) 64 (38)
4Q 62 (38) 56 (38) 64 (26)
FEV1 1Q 46 (12) 49 (15) 42 (10)
2Q 45 (12) 46 (13) 49 (14)
3Q 48 (14) 46 (14) 49 (13)
4Q 48 (14) 47 (12) 48 (14)
FEV1/FVC 1Q 39 (8) 45 (10) 39 (8)
2Q 42 (11) 42 (10) 43 (11)
3Q 45 (10) 43 (11) 45 (9)
4Q 42 (10) 40 (8) 42 (11)
TLC 1Q 116 (15) 115 (15) 118 (14)
2Q 115 (15) 116 (13) 117 (14)
3Q 117 (16) 111 (16) 113 (14)
4Q 117 (15) 124 (12) 116 (18)
CT Score 1Q 40 (13) 34 (14) 43 (11)
2Q 39 (10) 37 (12) 38 (14)
3Q 34 (12) 37 (13) 35 (11)
4Q 37 (15) 41 (12) 35 (14)
St. George 1Q 38 (17) 37 (14) 36 (9)
Total 2Q 33 (11) 37 (13) 37 (12)
3Q 38 (10) 35 (13) 35 (13)
4Q 40 (15) 40 (14) 42 (18)
The mean values of age, pack years, FEV1% predicted, FEV1/FVC % predicted, TLC % predicted, CT score and St. George questionnaire total score were calculated for
each quartile of MMP-1, -9 and TIMP-1 plasma protein expression. Bold indicates p,0.05 compared to quartile 1. Parentheses () indicate standard deviation.
doi:10.1371/journal.pone.0056352.t005
Table 6. Coefficients of correlation (R2) between elastase and
collagenase activity and COPD disease parameters.
Elastase Collagenase
Age 20.03 20.09
Pack years 0.13 0.00
FEV1 0.16 0.18
FEV1/FVC 0.05 0.00
TLC 0.18 0.12
CT score 0.01 0.11
DLCO 0.06 20.26
St. George total 20.13 20.03
The coefficient of correlation (R2) was calculated for elastase and collagenase
activity and age, pack years, FEV1, FEV1/FVC, TLC, CT score, DLCO and St.
George total score.
PFT parameters are reported in % predicted post bronchodilator.
doi:10.1371/journal.pone.0056352.t006
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Figure 5. Correlation between BALF MMP/TIMP levels and% change in FEV1. BALF protein levels for MMP-1, -9 and TIMP-1 were correlated
with the % change from baseline in FEV1 at 6, 9 and 18 months of follow up. The coefficient of determination (R2) was calculated for each value at
each time point.
doi:10.1371/journal.pone.0056352.g005
Figure 6. Correlation between plasma MMP/TIMP levels and % change in FEV1. Plasma protein levels for MMP-1, -9 and TIMP-1 were
correlated with the % change from baseline in FEV1 at 6, 9 and 18 months of follow up. The coefficient of determination (R2) was calculated for each
value at each time point.
doi:10.1371/journal.pone.0056352.g006
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